Aktuellt
SENASTE
Redeye is encouraged by today’s interim data from Vicore’s open-label phase II study in IPF, which analysed 21 patients out of 60 expected to enroll in the full trial, of which 7 patients reached 36 weeks of treatment. These early results indicate a strong and competitive treatment effect and a significantly positive reaction in the stock is warranted. We will return with a more thorough take after the conference call at 14:00 CET.
LÄS MER
